TRxADE HEALTH, Inc. (MEDS)
USD 7.59
(4.55%)
USD 7.59
(4.55%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 9.86 Million USD | 20.15% |
| 2022 | 8.2 Million USD | -6.86% |
| 2021 | 8.81 Million USD | 17.68% |
| 2020 | 7.48 Million USD | 71.08% |
| 2019 | 4.37 Million USD | 32.62% |
| 2018 | 3.3 Million USD | 45.5% |
| 2017 | 2.26 Million USD | -34.24% |
| 2016 | 3.44 Million USD | -14.85% |
| 2015 | 4.05 Million USD | 62.85% |
| 2014 | 2.48 Million USD | 18.7% |
| 2013 | 2.09 Million USD | 685.09% |
| 2012 | 266.95 Thousand USD | 0.0% |
| 2008 | 28.49 Million USD | 101003.38% |
| 2007 | 28.18 Thousand USD | 223.05% |
| 2006 | 8725.00 USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.48 Million USD | 39.14% |
| 2024 Q2 | 1.49 Million USD | -72.76% |
| 2023 Q4 | 3.94 Million USD | 54.69% |
| 2023 FY | 9.86 Million USD | 20.15% |
| 2023 Q1 | 1.9 Million USD | 4.62% |
| 2023 Q2 | 1.99 Million USD | 4.51% |
| 2023 Q3 | 2.54 Million USD | 28.1% |
| 2022 FY | 8.2 Million USD | -6.86% |
| 2022 Q4 | 1.82 Million USD | 0.63% |
| 2022 Q2 | 2.27 Million USD | -1.31% |
| 2022 Q3 | 1.8 Million USD | -20.45% |
| 2022 Q1 | 2.3 Million USD | 13.93% |
| 2021 Q3 | 2.57 Million USD | 17.84% |
| 2021 FY | 8.81 Million USD | 17.68% |
| 2021 Q4 | 2.02 Million USD | -21.48% |
| 2021 Q1 | 2.02 Million USD | 18.39% |
| 2021 Q2 | 2.18 Million USD | 7.81% |
| 2020 Q4 | 1.71 Million USD | -3.98% |
| 2020 Q2 | 2.54 Million USD | 93.78% |
| 2020 Q1 | 1.31 Million USD | 5.81% |
| 2020 Q3 | 1.78 Million USD | -29.79% |
| 2020 FY | 7.48 Million USD | 71.08% |
| 2019 FY | 4.37 Million USD | 32.62% |
| 2019 Q4 | 1.23 Million USD | 9.38% |
| 2019 Q2 | 1.03 Million USD | 9.76% |
| 2019 Q1 | 938.94 Thousand USD | -4.85% |
| 2019 Q3 | 1.13 Million USD | 9.91% |
| 2018 Q2 | 806.24 Thousand USD | 6.9% |
| 2018 Q1 | 754.19 Thousand USD | 108.54% |
| 2018 Q4 | 986.78 Thousand USD | 31.0% |
| 2018 Q3 | 753.29 Thousand USD | -6.57% |
| 2018 FY | 3.3 Million USD | 45.5% |
| 2017 Q3 | 646.25 Thousand USD | -1.48% |
| 2017 FY | 2.26 Million USD | -34.24% |
| 2017 Q4 | 361.65 Thousand USD | -44.04% |
| 2017 Q2 | 655.94 Thousand USD | 8.51% |
| 2017 Q1 | 604.49 Thousand USD | 184.16% |
| 2016 Q2 | 1.66 Million USD | 45.73% |
| 2016 FY | 3.44 Million USD | -14.85% |
| 2016 Q3 | 1.36 Million USD | -17.92% |
| 2016 Q1 | 1.14 Million USD | -13.41% |
| 2016 Q4 | -718.28 Thousand USD | -152.64% |
| 2015 Q3 | 1.01 Million USD | 24.91% |
| 2015 FY | 4.05 Million USD | 62.85% |
| 2015 Q1 | 908.32 Thousand USD | 5.15% |
| 2015 Q2 | 811.63 Thousand USD | -10.64% |
| 2015 Q4 | 1.31 Million USD | 29.95% |
| 2014 Q2 | 536.56 Thousand USD | 21.42% |
| 2014 Q3 | 645.36 Thousand USD | 20.28% |
| 2014 Q1 | 441.92 Thousand USD | -68.02% |
| 2014 Q4 | 863.8 Thousand USD | 33.85% |
| 2014 FY | 2.48 Million USD | 18.7% |
| 2013 FY | 2.09 Million USD | 685.09% |
| 2013 Q3 | 237.56 Thousand USD | -24.89% |
| 2013 Q1 | 160.03 Thousand USD | 0.0% |
| 2013 Q2 | 316.26 Thousand USD | 97.62% |
| 2013 Q4 | 1.38 Million USD | 481.72% |
| 2012 FY | 266.95 Thousand USD | 0.0% |
| 2009 Q3 | 4531.00 USD | 73.87% |
| 2009 Q1 | 18.87 Thousand USD | -99.93% |
| 2009 Q2 | 2606.00 USD | -86.2% |
| 2008 Q4 | 28.47 Million USD | 715824.56% |
| 2008 Q2 | 6462.00 USD | -8.73% |
| 2008 Q1 | 7080.00 USD | -17.66% |
| 2008 FY | 28.49 Million USD | 101003.38% |
| 2008 Q3 | 3978.00 USD | -38.44% |
| 2007 Q3 | 7256.00 USD | -38.06% |
| 2007 Q2 | 11.71 Thousand USD | 1795.47% |
| 2007 Q1 | 618.00 USD | -80.56% |
| 2007 FY | 28.18 Thousand USD | 223.05% |
| 2007 Q4 | 8598.00 USD | 18.5% |
| 2006 Q3 | 1578.00 USD | -59.96% |
| 2006 FY | 8725.00 USD | 0.0% |
| 2006 Q4 | 3179.00 USD | 101.46% |
| 2006 Q2 | 3941.00 USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | 13.47 Million USD | 26.829% |
| China Jo-Jo Drugstores, Inc. | 34.64 Million USD | 71.534% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 89.97 Million USD | 89.039% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 90.12 Million USD | 89.057% |
| Leafly Holdings, Inc. | 44.5 Million USD | 77.84% |
| LifeMD, Inc. | 148.13 Million USD | 93.343% |
| LifeMD, Inc. | 148.13 Million USD | 93.343% |
| PetMed Express, Inc. | 86.81 Million USD | 88.64% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.976% |